Clinical/Translational Cancer Immunotherapy

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
Sandip P Patel, Megan Othus, Young Kwang Chae, Tridu Huynh, Benjamin Tan, Timothy Kuzel, Christine McLeod, Gabby Lopez, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles Blanke, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009074; DOI: 10.1136/jitc-2024-009074
FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription
Xuemei Li, Lei Gao, Bofang Wang, Jike Hu, Yang Yu, Baohong Gu, Lin Xiang, Xiaomei Li, Haiyuan Li, Tao Zhang, Yunpeng Wang, Chenhui Ma, Jiahong Dong, Jianrong Lu, Alexandra Lucas, Hao Chen

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009565; DOI: 10.1136/jitc-2024-009565
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B Atkins, Meredith M Regan, David F McDermott

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009495; DOI: 10.1136/jitc-2024-009495
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers
Noboru Yamamoto, Shigehisa Kitano, Takafumi Koyama, Masafumi Ikeda, Hidenori Mizugaki, Takatsugu Narikiyo, Yuki Yamaguchi, Takaaki Ishida, Ryoko Takubo, Chika Ogami, Mayuko Sekiya, Yuki Nakagawa, Yasutoshi Kuboki

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009262; DOI: 10.1136/jitc-2024-009262
Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer
Niels E Wondergem, Iris H C Miedema, Rieneke van de Ven, Gerben J C Zwezerijnen, Pim de Graaf, K Hakki Karagozoglu, Jan-Jaap Hendrickx, Simone E J Eerenstein, Rolf J Bun, Dorien C Mulder, Jens Voortman, Ronald Boellaard, Albert D Windhorst, J Pascal Hagers, Laura A N Peferoen, Tanja D de Gruijl, Elisabeth Bloemena, Ruud H Brakenhoff, C René Leemans, C Willemien Menke-van der Houven van Oordt

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009278; DOI: 10.1136/jitc-2024-009278
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
Chandra C Ghosh, Lauren Cournoyer, Yujia Liu, Alizee Ballarin, Ilan B Layman, Jason LaPorte, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha, Prajna Guha, Steven C Katz, Diwakar Davar

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008837; DOI: 10.1136/jitc-2024-008837
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
Patrick Tiongco Magahis, Tara Corso, Pamela Livingstone, Erika Tom, Amitabh Srivastava, Michael Postow, David Faleck

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009051; DOI: 10.1136/jitc-2024-009051
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary study
Gaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, Najeeb Halabi, Eliane Mery-Lamarche, Noemie Thebault, Clara-Maria Scarlata, Marie Michelas, Anne-Sophie Navarro, Gwenaël Ferron, Fabrice Lecuru, Patrice Mathevet, Jonathan Khalifa, Maha Ayyoub, Arash Rafii, Alejandra Martinez

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008734; DOI: 10.1136/jitc-2023-008734
Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment
Yoonjeong Choi, Seong A Kim, Hanul Jung, Eunhae Kim, Yoon Kyoung Kim, Seohyun Kim, Jaehyun Kim, Yeji Lee, Min Kyoung Jo, Jiwan Woo, Yakdol Cho, Dongjoo Lee, Hongyoon Choi, Cherlhyun Jeong, Gi-Hoon Nam, Minsu Kwon, In-San Kim

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e008864; DOI: 10.1136/jitc-2024-008864
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species
Man Zhu, Wenjun Tang, Xiaoyu Tang, Zeren Zhu, Yina Jiang, Ammar Sarwar, Hongmei Zhang, Dake Chu, Zixi Zhang, Yanmin Zhang

Journal for ImmunoTherapy of Cancer Jul 2024, 12 (7) e009099; DOI: 10.1136/jitc-2024-009099

Main menu

Clinical/Translational Cancer Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical/Translational Cancer Immunotherapy

Pages